Literature DB >> 16618941

Effects of long-term androgen administration on breast tissue of female-to-male transsexuals.

Margrita H Slagter1, Louis J G Gooren, Andreas Scorilas, Constantina D Petraki, Eleftherios P Diamandis.   

Abstract

Our aim was to examine the effects of androgen administration on breast tissue histology of female-to-male transsexuals and to study the immunohistochemical expression of three human tissue kallikreins, hK3 (PSA), hK6, and hK10. We studied 23 female-to-male transsexuals who were treated with injectable testosterone for 18-24 months. We also used 10 control female breast tissues. All tissues were fixed in buffered formalin, embedded in paraffin, and examined by hematoxylin-eosin staining and immunohistochemical staining for PSA, hK6, and hK10. Females treated with androgens exhibited similar involutionary changes as those seen in breast of menopausal women, such as marked reduction of glandular tissue, involution of the lobuloalveolar structures, and prominence of fibrous connective tissue, but presence of only small amounts of fat tissue. Fibrocystic lesions were generally not observed. In immunohistochemistry, in control breast tissues, we found moderate to strong cytoplasmic immunoexpression of hK6 and hK10 in the epithelial ductal and lobuloalveolar structures, but myoepithelial cells were negative. Luminal secretions were also positive. In menopausal breast, the immunoexpression of hK6 and hK10 was weaker and focal. No control case showed immunoexpression for PSA. In female-to-male transsexuals, one case showed focal PSA cytoplasmic immunoexpression in the epithelium of moderately involuting lobules. Long-term administration of androgens in female-to-male transsexuals causes marked reduction of glandular tissue and prominence of fibrous connective tissue. These changes are similar to those observed at the end-stage of menopausal mammary involution.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618941     DOI: 10.1369/jhc.6A6928.2006

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  8 in total

Review 1.  Cross-sex hormone therapy for gender dysphoria.

Authors:  B Fabris; S Bernardi; C Trombetta
Journal:  J Endocrinol Invest       Date:  2014-11-18       Impact factor: 4.256

2.  The Role of Androgens in Normal and Malignant Breast Tissue.

Authors:  Katharina Tiefenbacher; Günter Daxenbichler
Journal:  Breast Care (Basel)       Date:  2008-10-16       Impact factor: 2.860

Review 3.  Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review.

Authors:  Harsh Patel; Victor Arruarana; Lucille Yao; Xiaojiang Cui; Edward Ray
Journal:  Endocrine       Date:  2020-02-17       Impact factor: 3.633

Review 4.  Routine Screening for Transgender and Gender Diverse Adults Taking Gender-Affirming Hormone Therapy: a Narrative Review.

Authors:  Sean J Iwamoto; Frances Grimstad; Michael S Irwig; Micol S Rothman
Journal:  J Gen Intern Med       Date:  2021-02-05       Impact factor: 5.128

5.  Breast Cancer in the Transgender Population.

Authors:  Andrea Fehl; Shannon Ferrari; Zoe Wecht; Margaret Rosenzweig
Journal:  J Adv Pract Oncol       Date:  2019-03-01

6.  Vaginal bleeding and spotting in transgender men after initiation of testosterone therapy: A prospective cohort study (ENIGI).

Authors:  Justine Defreyne; Yuran Vanwonterghem; Sarah Collet; Sean J Iwamoto; Chantal M Wiepjes; Alessandra D Fisher; Thomas Schreiner; Martin Den Heijer; Guy T'Sjoen
Journal:  Int J Transgend Health       Date:  2020-02-12

Review 7.  Breast Imaging of Transgender Individuals: A Review.

Authors:  Emily B Sonnenblick; Ami D Shah; Zil Goldstein; Tamar Reisman
Journal:  Curr Radiol Rep       Date:  2018-01-18

8.  Breast malignancy in female-to-male transsexuals: systematic review, case report, and recommendations for screening.

Authors:  Anne C Fledderus; H Antoine Gout; Aernout C Ogilvie; Dorothea K G van Loenen
Journal:  Breast       Date:  2020-07-02       Impact factor: 4.380

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.